Current Diabetes Reports

, Volume 9, Issue 1, pp 51–59 | Cite as

Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap

  • Roger S. McIntyre
  • Natalie L. Rasgon
  • David E. Kemp
  • Ha T. Nguyen
  • Candy W. Y. Law
  • Valerie H. Taylor
  • Hanna O. Woldeyohannes
  • Mohammad T. Alsuwaidan
  • Joanna K. Soczynska
  • Byungsu Kim
  • Maria T. Lourenco
  • Linda S. Kahn
  • Benjamin I. Goldstein


The metabolic syndrome and its components are associated with depressive symptomatology. This article discusses the rate of co-occurrence and the points of pathophysiologic commonality between the metabolic syndrome and major depressive disorder.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gans RO: The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006, 90:573–591.PubMedCrossRefGoogle Scholar
  2. 2.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.PubMedCrossRefGoogle Scholar
  3. 3.
    Hu G, Qiao Q, Tuomilehto J, et al.: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066–1076.PubMedCrossRefGoogle Scholar
  4. 4.
    Laaksonen DE, Lakka HM, Niskanen LK, et al.: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070–1077.PubMedCrossRefGoogle Scholar
  5. 5.
    Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.PubMedCrossRefGoogle Scholar
  6. 6.
    Rasgon NL, Altshuler LL, Fairbanks L, et al.: Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005, 7:246–259.PubMedCrossRefGoogle Scholar
  7. 7.
    Lindley SE, Schroder CM, O’Hara R, Fazio S: Insulin resistance in schizophrenia, major depression, and bipolar disorder. In Insulin Resistance Syndrome and Neuropsychiatric Disease. Edited by Rasgon NL. New York: Informa Healthcare; 2008:49–86.Google Scholar
  8. 8.
    Taylor V, Macqueen G: Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034–1041.PubMedGoogle Scholar
  9. 9.
    McEvoy JP, Meyer JM, Goff DC, et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Fagiolini A, Frank E, Scott JA, et al.: Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005, 7:424–430.PubMedCrossRefGoogle Scholar
  11. 11.
    Fagiolini A, Frank E, Turkin S, et al.: Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 2008, 69:678–679.PubMedCrossRefGoogle Scholar
  12. 12.
    Van WR, De HM, Van ED, et al.: Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008, 10:342–348.CrossRefGoogle Scholar
  13. 13.
    Gavard JA, Lustman PJ, Clouse RE: Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993, 16:1167–1178.PubMedCrossRefGoogle Scholar
  14. 14.
    Teixeira PJ, Rocha FL: The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007, 29:330–336.PubMedCrossRefGoogle Scholar
  15. 15.
    Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al.: Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008, 23:e1–e5.Google Scholar
  16. 16.
    McIntyre RS, Soczynska JK, Konarski JZ, et al.: Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry 2007, 19:257–264.PubMedCrossRefGoogle Scholar
  17. 17.
    McIntyre RS, Soczynska JK, Konarski JZ, et al.: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006, 5:157–168.PubMedCrossRefGoogle Scholar
  18. 18.
    McIntyre RS, Soczynska JK, Konarski JZ, et al.: The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006, 5:523–537.PubMedCrossRefGoogle Scholar
  19. 19.
    Kinder LS, Carnethon MR, Palaniappan LP, et al.: Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004, 66:316–322.PubMedCrossRefGoogle Scholar
  20. 20.
    Gil K, Radzillowicz P, Zdrojewski T, et al.: Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project. Kardiol Pol 2006, 64:464–469.PubMedCrossRefGoogle Scholar
  21. 21.
    Raikkonen K, Matthews KA, Kuller LH: Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care 2007, 30:872–877.PubMedCrossRefGoogle Scholar
  22. 22.
    Roos C, Lidfeldt J, Agardh CD, et al.: Insulin resistance and self-rated symptoms of depression in Swedish women with risk factors for diabetes: the Women’s Health in the Lund Area study. Metabolism 2007, 56:825–829.PubMedCrossRefGoogle Scholar
  23. 23.
    Raikkonen K, Matthews KA, Kuller LH: The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002, 51:1573–1577.PubMedCrossRefGoogle Scholar
  24. 24.
    McCaffery JM, Niaura R, Todaro JF, et al.: Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study. Psychosom Med 2003, 65:490–497.PubMedCrossRefGoogle Scholar
  25. 25.
    Heiskanen TH, Niskanen LK, Hintikka JJ, et al.: Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006, 67:1422–1427.PubMedCrossRefGoogle Scholar
  26. 26.
    Skilton MR, Moulin P, Terra JL, et al.: Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 2007, 62:1251–1257.PubMedCrossRefGoogle Scholar
  27. 27.
    Vaccarino V, McClure C, Johnson BD, et al.: Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008, 70:40–48.PubMedCrossRefGoogle Scholar
  28. 28.
    Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993, 270:1819–1825.PubMedCrossRefGoogle Scholar
  29. 29.
    Osby U, Brandt L, Correia N, et al.: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58:844–850.PubMedCrossRefGoogle Scholar
  30. 30.
    Kashyap S, Belfort R, Gastaldelli A, et al.: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003, 52:2461–2474.PubMedCrossRefGoogle Scholar
  31. 31.
    Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  32. 32.
    Sarafidis PA, Bakris GL: Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 2007, 21:12–19.PubMedCrossRefGoogle Scholar
  33. 33.
    McIntyre RS, Konarski JZ, Wilkins K, et al.: Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006, 51:274–280.PubMedCrossRefGoogle Scholar
  34. 34.
    Lapidus L, Bengtsson C, Larsson B, et al.: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 1984, 289:1257–1261.Google Scholar
  35. 35.
    Kalkhoff RK, Hartz AH, Rupley D, et al.: Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med 1983, 102:621–627.PubMedGoogle Scholar
  36. 36.
    Peiris AN, Sothmann MS, Hennes MI, et al.: Relative contribution of obesity and body fat distribution to alterations in glucose insulin homeostasis: predictive values of selected indices in premenopausal women. Am J Clin Nutr 1989, 49:758–764.PubMedGoogle Scholar
  37. 37.
    Lee ES, Kim YH, Beck SH, et al.: Depressive mood and abdominal fat distribution in overweight premenopausal women. Obes Res 2005, 13:320–325.PubMedCrossRefGoogle Scholar
  38. 38.
    Moreira RO, Marca KF, Appolinario JC, et al.: Increased waist circumference is associated with an increased prevalence of mood disorders and depressive symptoms in obese women. Eat Weight Disord 2007, 12:35–40.PubMedGoogle Scholar
  39. 39.
    Southwick SM, Vythilingam M, Charney DS: The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol 2005, 1:255–291.PubMedCrossRefGoogle Scholar
  40. 40.
    Banki CM, Karmacsi L, Bissette G, et al.: CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992, 2:107–113.PubMedCrossRefGoogle Scholar
  41. 41.
    Kapczinski F, Vieta E, Andreazza AC, et al.: Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32:675–692.PubMedCrossRefGoogle Scholar
  42. 42.
    Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3:169–178.PubMedCrossRefGoogle Scholar
  43. 43.
    Girgis RR, Javitch JA, Lieberman JA:Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008, 13:918–929.PubMedCrossRefGoogle Scholar
  44. 44.
    Gould TD, Manji HK: Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223–1237.PubMedGoogle Scholar
  45. 45.
    Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Kiecolt-Glaser JK, Glaser R: Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002, 53:873–876.PubMedCrossRefGoogle Scholar
  47. 47.
    Selley ML: Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004, 80:249–256.PubMedCrossRefGoogle Scholar
  48. 48.
    Sarandol A, Sarandol E, Eker SS, et al.: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22:67–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Sarandol A, Sarandol E, Eker SS, et al.: Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1103–1108.PubMedCrossRefGoogle Scholar
  50. 50.
    Maiese K, Morhan SD, Chong ZZ: Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007, 4:63–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Forlenza MJ, Miller GE: Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosom Med 2006, 68:1–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Carney RM, Freedland KE, Veith RC: Depression, the autonomic nervous system, and coronary heart disease. Psychosom Med 2005, 67(Suppl 1):S29–S33.PubMedCrossRefGoogle Scholar
  53. 53.
    Carnethon MR, Golden SH, Folsom AR, et al.: Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987–1998. Circulation 2003, 107:2190–2195.PubMedCrossRefGoogle Scholar
  54. 54.
    Golden RN, Markey SP, Risby ED, et al.: Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 1988, 45:150–154.PubMedGoogle Scholar
  55. 55.
    Benthem L, Keizer K, Wiegman CH et al.: Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation. Am J Physiol Endocrinol Metab 2000, 279:E1286–E1293.PubMedGoogle Scholar
  56. 56.
    McIntyre RS, McElroy SL, Konarski JZ, et al.: Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry 2007, 68:1352–1357.PubMedCrossRefGoogle Scholar
  57. 57.
    Rasgon NL, Kenna HA: Insulin resistance in depressive disorders and Alzheimer’s disease: revisiting the missing link hypothesis. Neurobiol Aging 2005, 26(Suppl 1):103–107.PubMedCrossRefGoogle Scholar
  58. 58.
    Dunn AL, Trivedi MH, Kampert JB, et al.: Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005, 28:1–8.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • Roger S. McIntyre
    • 1
  • Natalie L. Rasgon
  • David E. Kemp
  • Ha T. Nguyen
  • Candy W. Y. Law
  • Valerie H. Taylor
  • Hanna O. Woldeyohannes
  • Mohammad T. Alsuwaidan
  • Joanna K. Soczynska
  • Byungsu Kim
  • Maria T. Lourenco
  • Linda S. Kahn
  • Benjamin I. Goldstein
  1. 1.Mood Disorders Psychopharmacology UnitUniversity Health NetworkTorontoCanada

Personalised recommendations